A Phase 2 interventional study of Quinidine and Verapamil in Short-coupled Idiopathic Ventricular Fibrillation, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Enrolling by invitation at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Ventricular Fibrillation with a site in Netherlands — 6 open to participants now, 6 under way, 1 of them phase 3. Ventricular Fibrillation · Netherlands.
Among the 17 studies in Ventricular Fibrillation with a site in Netherlands, this one is the 11th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 2, and was the 13th registered.
186 studies on the registry are indexed under Ventricular Fibrillation; 37 are open to participants now.
Browse Ventricular Fibrillation studies →6 of the 17 studies in Ventricular Fibrillation with a site in Netherlands are open now. Recruiting first, the newest first:
Catharina Ziekenhuis Eindhoven · Sites in Netherlands
Ages 18+
AtaCor Medical, Inc. · Sites in Netherlands, United States
Ages 18+
Gabriel Riva · Sites in Netherlands, Spain, Sweden
Ages 18+
Catharina Ziekenhuis Eindhoven · Sites in Netherlands
Ages 18+
Maastricht University Medical Center · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 22 Ventricular Fibrillation studies recruiting now, 19 (86%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 1
First in 2005; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 192 across 89 interventional studies indexed under Ventricular Fibrillation.
Median enrollment 280 across the 11 interventional studies, 401 across the 6 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 17 have an industry lead sponsor. The 10 most frequent:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is the lead sponsor of 533 studies on the registry; 182 are open to participants now.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) has 3 studies filed under Ventricular Fibrillation — fewer than ten, so there is no comparison to draw.
1 of the studies in Ventricular Fibrillation with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07324031AtaCor Medical, Inc.Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study | 2027-08-31 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Ventricular Fibrillation with a site in Netherlands, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Short-coupled idiopathic ventricular fibrillation (IVF) is a rare subtype of idiopathic ventricular fibrillation that is characterized by ventricular fibrillation (VF) or polymorphic ventricular tachycardia (PVT) initiated by a short-coupled premature ventricular contraction (PVC). Although patients are protected from sudden cardiac death by an implantable cardioverter-defibrillator (ICD), additional antiarrhythmic drug therapy is indispensable as recurrent ICD shocks are not uncommon and can negatively affect quality of life. Verapamil and quinidine have been suggested as effective antiarrhythmic drugs, but at present it is unknown whether these drugs reduce the incidence of arrhythmic events. This pilot study will provide insight into the advisability and feasibility of a randomized controlled trial (RCT) and provide data needed to determine the most appropriate design and the sample size.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least one of the following 3 principal diagnostic criteria for short-coupled IVF:
A. Diagnosis of short-coupled IVF, based on any documentation (i.e., , Holter monitor, device electrogram (EGM), or telemetry) of PVT of ≥3 consecutive beats or VF initiated by a PVC with a coupling interval \<350 ms B. Isolated PVCs with a coupling interval \<350 ms during the index admission after SCA based on a shockable rhythm or (presumed) arrhythmogenic syncope C. DPP6 haplotype carrier
Exclusion Criteria:
Brugada syndrome, early repolarization syndrome or catecholaminergic polymorphic ventricular tachycardia
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For this arm, patients will be treated with quinidine 200 mg thrice daily during period A. During period B, patients will be treated with verapamil 320-480mg daily during period B. The duration of the periods is different for each patient and depends on the time of inclusion.
Drug: Quinidine · Drug: Verapamil
For this arm, patients will be treated with verapamil 320-480mg daily during period A. During period B, patients will be treated with quinidine 200 mg thrice daily during period A. The duration of the periods is different for each patient and depends on the time of inclusion.
Drug: Quinidine · Drug: Verapamil
Sustained ventricular arrhythmia
Sustained ventricular arrhythmia, assessed using the severity scoring system. A subject will be scored in each treatment period according to the scoring system by the Endpoint Classification Committee. The highest applicable score will be used. Ventricular arrhythmia scoring system: 0= No arrhythmic events 1. A single arrhythmic event 2. Electrical storm (≥3 episodes of sustained PVT/VF within 24 hours) 3. ≥2, but \<5 arrhythmic events 4. ≥5 arrhythmic events
Time frame: 3 years
Time to first arrhythmic event
The time between the first day in each period and the first arrhythmic event in that period
Time frame: 3 years
Incidence of quinidine-induced torsade de pointes
Time frame: 3 years
Incidence of sustained monomorphic ventricular tachycardia
Time frame: 3 years
Number of inappropriate ICD shocks
Time frame: 3 years
Started Oct 2022 (actual). Primary completion is estimated for Sep 2025, 35 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Quinidine · Verapamil
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) →